AVRO
Price
$1.21
Change
+$0.03 (+2.54%)
Updated
Apr 26, 6:59 PM EST
11 days until earnings call
EDIT
Price
$5.32
Change
+$0.10 (+1.92%)
Updated
Apr 26, 6:59 PM EST
3 days until earnings call
Ad is loading...

AVRO vs EDIT ᐉ Comparison: Which is Better to Invest?

Header iconAVRO vs EDIT Comparison
Open Charts AVRO vs EDITBanner chart's image
AVROBIO
Price$1.21
Change+$0.03 (+2.54%)
Volume$161.37K
CapitalizationN/A
Editas Medicine
Price$5.32
Change+$0.10 (+1.92%)
Volume$848.24K
CapitalizationN/A
View a ticker or compare two or three
AVRO vs EDIT Comparison Chart

Loading...

AVRODaily Signal changed days agoGain/Loss if shorted
 
Show more...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AVRO vs. EDIT commentary
Apr 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVRO is a StrongSell and EDIT is a Hold.

COMPARISON
Comparison
Apr 28, 2024
Stock price -- (AVRO: $1.21 vs. EDIT: $5.32)
Brand notoriety: AVRO and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVRO: 119% vs. EDIT: 68%
Market capitalization -- AVRO: $54.3M vs. EDIT: $437.49M
AVRO [@Biotechnology] is valued at $54.3M. EDIT’s [@Biotechnology] market capitalization is $437.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $568.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVRO’s FA Score shows that 1 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • AVRO’s FA Score: 1 green, 4 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, AVRO is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVRO’s TA Score shows that 2 TA indicator(s) are bullish while EDIT’s TA Score has 2 bullish TA indicator(s).

  • AVRO’s TA Score: 2 bullish, 5 bearish.
  • EDIT’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than AVRO.

Price Growth

AVRO (@Biotechnology) experienced а +0.83% price change this week, while EDIT (@Biotechnology) price change was -3.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.69%. For the same industry, the average monthly price growth was -8.16%, and the average quarterly price growth was +1262.42%.

Reported Earning Dates

AVRO is expected to report earnings on Aug 08, 2024.

EDIT is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Biotechnology (+1.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AVRO with price predictions.
OPEN
A.I.dvisor published
a Summary for EDIT with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
EDIT($437M) has a higher market cap than AVRO($54.3M). AVRO YTD gains are higher at: -11.029 vs. EDIT (-47.483).
AVROEDITAVRO / EDIT
Capitalization54.3M437M12%
EBITDAN/AN/A-
Gain YTD-11.029-47.48323%
P/E Ratio4.48N/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
AVRO vs EDIT: Fundamental Ratings
AVRO
EDIT
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
5997
PRICE GROWTH RATING
1..100
6088
P/E GROWTH RATING
1..100
63100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (24) in the Biotechnology industry is in the same range as AVRO (30). This means that EDIT’s stock grew similarly to AVRO’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AVRO (100). This means that EDIT’s stock grew similarly to AVRO’s over the last 12 months.

AVRO's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for EDIT (97). This means that AVRO’s stock grew somewhat faster than EDIT’s over the last 12 months.

AVRO's Price Growth Rating (60) in the Biotechnology industry is in the same range as EDIT (88). This means that AVRO’s stock grew similarly to EDIT’s over the last 12 months.

AVRO's P/E Growth Rating (63) in the Biotechnology industry is somewhat better than the same rating for EDIT (100). This means that AVRO’s stock grew somewhat faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVROEDIT
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
N/A
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
AVRODaily Signal changed days agoGain/Loss if shorted
 
Show more...
EDITDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ABIO3.580.10
+2.87%
ARCA biopharma
NSSC43.860.48
+1.11%
NAPCO Security Technologies
FLS46.760.41
+0.88%
Flowserve Corp
GILD65.420.15
+0.23%
Gilead Sciences
ADCT4.34-0.10
-2.25%
ADC Therapeutics SA

AVRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVRO has been loosely correlated with HEPA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AVRO jumps, then HEPA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVRO
1D Price
Change %
AVRO100%
+2.11%
HEPA - AVRO
46%
Loosely correlated
+6.20%
FBIO - AVRO
42%
Loosely correlated
N/A
INO - AVRO
39%
Loosely correlated
+4.40%
ORMP - AVRO
39%
Loosely correlated
+6.96%
EDIT - AVRO
39%
Loosely correlated
+1.92%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been closely correlated with NTLA. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+1.92%
NTLA - EDIT
68%
Closely correlated
+3.70%
BEAM - EDIT
63%
Loosely correlated
-1.02%
AXON - EDIT
52%
Loosely correlated
+0.65%
VCYT - EDIT
49%
Loosely correlated
-0.87%
ALLO - EDIT
48%
Loosely correlated
+1.23%
More